·糖尿病与神经疾病·

　　【摘要】 目的 观察降钙素对T2DM周围神经痛(PDN)伴骨质疏松患者的疗效。 方法 选择T2DM+PDN伴骨质疏松症患者39例，随机分为试验组(20例)和对照组(19例)。试验组予降钙素(益盖宁，20 μ，2次/周)，对照组予骨质疏松症基础治疗药物(钙剂、维生素D)。分别于试验开始时(0周)，试验后2、4、8、12周进行疼痛评分。疼痛评分选用划线记录法(VAS)和面部表情量表法(FS)，同时将患者对疗效的主观感觉分为无效、有效、显效。 结果 客观分析法提示试验组和对照组间疗效差异有统计学意义(VAS：P=0.014，FS：P=0.014)。患者主观感觉第2周差异无统计学意义(P=0.076)，但第4、8、12周差异有统计学意义。 结论 降钙素对T2DM+PDN伴骨质疏松患者具有改善作用，且呈时间依赖性，4周以上疗效显著。

　　【关键词】 糖尿病，2型;糖尿病周围神经痛;骨质疏松症;降钙素;β-内啡肽，

Effect of calcitonin in osteoporotic patients with diabetic peripheral neuropathy CUI Ran, CHENG Xiao-yun, YANG Peng, et al. Department of Endocrinology, The Tenth People’s Hospital of Tongji University, Shanghai 200072, China

Corresponding author: LI Wen-jun, E-mail: liwenjun1@189.cn

　　【Abstract】Objective To investigate the effect of calcitonin on osteoporotic patients with painful diabetic neuropathy. Methods Thirty-nine osteroprosis patients with T2DM and diabetic neuropathy were recruited for this study. They were randomized into the experiment group, n=20, and the control group, n=19. The experiment group was administered calcitonin, 20μ, twice a week, and the control group was given the basic treatment for osteoporosis (calcium, vitamin D). Pain was assessed at 0, 2, 4, 8, and 12 weeks of treatment using the visual analogue scale (VAS) and the Wong-Baker Face Scale (FS). At the same time, the patients’ subjective assessment of treatment was recorded as recorded as ineffective, effective, and remarkably effective. Results Both VAS and FS scores showed that the difference of effect between the experiment and control groups was statistically significant (VAS: P=0.014, FS: P=0.014). The patients’ subjective assessment of treatment of the 2nd week was not significantly different (P=0.076), while that of the 4th, 8th, and 12th weeks was significantly different. Conclusion Calcitonin is effective in improving the symptoms of T2DM+PDN patients in a time-dependant manner, and it is remarkably effective in the treatment over 4 weeks.

　　【Key words】Diabetes mellitus, type 2; Diabetic perineuralgia; Osteoporosis; Calcitonin; β-endorphin